

# Initiation and Adjusting Insulin Therapy, am I doing it right? DMT2

Michelle Mangual, MD

Diplomate of the American Board of Internal Medicine and Endocrinology, Diabetes and Metabolism

Diplomate of the American Board of Clinical Lipidology

November 14, 2021



100 Years of Insulin Therapy: A long Successful Path



# Disclosures

- No conflict of interest



100 Years of Insulin Therapy: A long Successful Path



# Learning Objectives


- Identify patient and disease characteristics that help providers to establish appropriate individual glycemic targets.
- Discuss when to initiate insulin therapy based on current ADA Standards of Medical Care and AACE.
- Develop skills for calculating patients' initial insulin dosage and titrating insulin dosages based on individualized glycemic targets.
- Understand the concept of overbasalization and how to avoid it.
- Better understand how to advise patients on their options with regard to insulin therapy regimens.



100 Years of Insulin Therapy: A long Successful Path



# Approach to Individualization of Glycemic Targets





## Glycemic Recommendations for Many Non-Pregnant Adults With Diabetes

<b>A1c</b>	<7%*
<b>Preprandial capillary plasma glucose</b>	80-130 mg/dl*
<b>Peak postprandial plasma glucose<sup>^</sup></b>	<180 mg/dl*

- \*More stringent glycemic goals maybe appropriate for individual patients
- <sup>^</sup>Postprandial glucose measurements should be made 1-2 hours after the beginning of the meal, generally peak levels in patients with diabetes.

# AACE Glycemic Control Algorithm: When to Consider Insulin Therapy in Patients with T2DM

Strong  
recommendation  
to initiate therapy

- A1C >9.0% and/or symptomatic hyperglycemia; with or without other antihyperglycemic agents

Option for  
consideration as  
initial therapy

- In combination with 1-2 other antihyperglycemic agents when A1C is  $\geq 7.5\%$ -9.0%


As treatment  
intensification

- Added to monotherapy or dual therapy when A1C goals are not met after 3 months

Choice of treatment depends on patient and medication




# Therapeutic inertia in the treatment of hyperglycemia in patients with type 2 diabetes: A systematic review





Is A1c above target despite dual/triple therapy?  
What's next?





# The Treat-to-Target Trial

Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

MATTHEW C. RIDDLE, MD<sup>1</sup>  
JULIO ROSENSTOCK, MD<sup>2</sup>  
JOHN GERICH, MD<sup>3</sup>

ON BEHALF OF THE INSULIN GLARGINE 4002  
STUDY INVESTIGATORS\*

The first study to force-titrate insulin dosages to achieve a prespecified treatment goal; enabled comparison of safety endpoints to establish risk-benefit of a newer basal insulin



Matthew C. Riddle et al. Dia Care 2003;26:3080-3086



100 Years of Insulin Therapy: A long Successful Path





# Effects on glycemic parameters of adding insulin to patients previously treated with 1-2 oral agents with A1c >7.5% ( $n=756$ )



Matthew C. Riddle et al. Dia Care 2003;26:3080-3086



# Cumulative Number of Hypoglycemia Events: The Treat-to-Target Trial



Matthew C. Riddle et al. Dia Care 2003;26:3080-3086




100 Years of Insulin Therapy: A long Successful Path



# Basal Insulin Added to Oral Agents Improves Glycemic Control


24-week noninferiority trial of 973 insulin-naïve patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs



- Similar hypoglycemia rates (<30% symptomatic)
- Changes in body weight (kg):
  - Insulin glargine: 1.4
  - Insulin detemir: 0.6 ( $P < 0.001$ )
- Final insulin doses (units/day):
  - Insulin glargine: 43.5
  - Insulin detemir: 76.5 ( $P < 0.001$ )




# More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial



# Initiation of basal insulin



If A1c >8%  
consider starting  
dose 0.2-0.3 units/kg



Initiate insulin with a  
single injection of a basal  
insulin

Bedtime or morning long-  
acting insulin or bedtime  
intermediate-acting  
insulin



Daily dose: 10  
units or 0.1-0.2  
units/Kg

American Diabetes Association Dia Care 2021;44:S111-S124.  
Garber A J, et al. Endocr Pract. 2020;26(1):107-139



100 Years of Insulin Therapy: A long Successful Path






# Titration of Basal Insulin

## START

Basal Insulin

Daily dose: 10 units *or* 0.1-0.2 units/kg




Check FPG daily with  
SMBG

- Patient self-titration is more effective
- Set FPG target that correlates to A1c target

## ADJUST

Choose evidence-based titration algorithm  
(e.g., increase 2 units every 3 days) to  
reach FPG target without hypoglycemia



If signs/symptoms of  
hypoglycemia, address cause and  
reduce insulin dose by 10-20%



Continue regimen and check A1c  
every 3 months

American Diabetes Association Dia Care 2021;44:S111-S124.  
Inzucchi, SE, et al. Dia Care 2015;38:140-149



# Assess Adequacy of Basal Insulin Dose

Overbasalization?  
Need to consider  
adjunctive therapies?

- Basal dose >0.5 IU/kg
- Elevated bedtime-morning
- Hypoglycemia
- High variability

Open Access

Research

**BMJ Open  
Diabetes  
Research  
& Care**

## **BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin**


Ariel Zisman,<sup>1</sup> Francienid Morales,<sup>2</sup> John Stewart,<sup>3</sup> Andreas Stuhr,<sup>4</sup>  
Aleksandra Vlajnic,<sup>2</sup> Rong Zhou<sup>5</sup>

# Assess Adequacy of Basal Insulin Dose

Date	Fasting	Bedtime
Mon	100 mg/dl	180 mg/dl
Tue	95 mg/dl	175mg/dl
Wed	80 mg/dl	168 mg/dl
Thu	110 mg/dl	200 mg/dl
Fri	105 mg/dl	190 mg/dl
Sat	99 mg/dl	170 mg/dl


## AMBULATORY GLUCOSE PROFILE (AGP)

AGP is a summary of glucose values from the report period, with median (50%) and other percentiles shown as if occurring in a single day.



## DAILY GLUCOSE PROFILES

Each daily profile represents a midnight to midnight period with the date displayed in the top-left corner.




100 Years of Insulin Therapy: A long Successful Path





# Prandial Insulin Intensification



American Diabetes Association Dia Care 2021;44:S111-S124.

# When Basal Insulin Is Not Enough to Control Glycemia

- Patients whose glycemia remains uncontrolled while receiving basal insulin in combination with oral agents or GLP-1 RAs may require mealtime insulin to cover postprandial hyperglycemia.<sup>1,2</sup>

## Basal Plus Prandial

Prandial insulin  
added to 1,2, or 3  
meals<sup>1,2</sup>

## Basal-Bolus

Prandial insulin  
added to every  
meal<sup>1</sup>

## Premixed

Combination short  
and intermediate  
acting insulin<sup>2</sup>




1. Garber A J, et al. Endocr Pract. 2020;26(1):107-139. 2. American Diabetes Association Dia Care 2021;44:S111-S124.

100 Years of Insulin Therapy: A long Successful Path




# Prandial Insulin Intensification





# Prandial Insulin Intensification



# Prandial Insulin Intensification

	Breakfast		Lunch		Dinner		Bedtime
	Pre	Post	Pre	Post	Pre	Post	
Mon	130	160	146	200	180	200	190
Tue	110	140	150	220	190	210	200
Wed	105	145	143	199	178	220	180
Thu	125	158	138	198	170	190	174
Fri	113	161	130	190	168	185	185
Sat	108	149	147	207	191	210	192
Sun	129	165	138	198	178	187	210

BeAm = >60 mg/dl  
Reduced Basal Insulin  
by 4 U or 10%


Add 4 U lispro before  
lunch



100 Years of Insulin Therapy: A long Successful Path



# Prandial Insulin Intensification



# Using Premixed Insulin

## Pros

- Only one co-pay
- Patient with a predictable schedule with regular meals and with a lower risk of hypoglycemia.
- Patients often need fewer shots (1-2 per day)
- Premixed R & N has the lowest cost.
- Premixed Humalog 50/50 for patients with high carbohydrate meals.

## Cons

- Patients must eat regular meals or they will be at a greater risk for hypoglycemia.
- More nocturnal hypoglycemia
- Premixed Regular & NPH has a greater risk for hypoglycemia.
- There is an increased need for between meal snacks.



100 Years of Insulin Therapy: A long Successful Path





# STARTING PREMIXED ANALOG INSULIN: WHEN TO TEST AND HOW TO ADJUST YOUR DOSE

(USING HUMALOG MIX 75/25%\* OR NOVOLOG MIX 70/30%\* | For Patients Who Are Not On Basal Insulin)

## HOW TO START PREMIXED INSULIN

The first dose should be 10% of the patient's weight in pounds (i.e. 220 lbs = 22 units) taken once daily at the largest meal.

When Premixed Insulin Is Taken:	When To Test Blood Sugar:	If The Blood Sugar Results Are:	Then You Should:
At Breakfast	Before Dinner	Under 80	Subtract 2 Units Every 3-5 Days Until Blood Sugar is 80–130 Before Dinner
		80–130	Do Not Adjust
		Over 130	Add 2 Units Every 3-5 Days Until Blood Sugar is 80–130 Before Dinner
At Dinner	Before Bed	80–130	Eat a Small Snack
		130–180	For Most People on Premixed Insulin, This is a Good Blood Sugar Goal to Have in Order to Avoid Hypoglycemia During the Night.
	Before Breakfast	Under 80	Subtract 2 Units Every 3–5 Days Until Blood Sugar is 80–130 Before Breakfast
		80–130	Do Not Adjust Dose
		Over 130	Add 2 Units Every 3–5 Days Until Blood Sugar is 80–130 Before Breakfast
		If blood sugar is under 70, drink 1/2 cup of juice or soda or eat something that contains sugar. You can also take glucose tablets to bring your blood sugar into normal range. Let your physician/care team know that you had low blood sugar.	



# Considering oral therapy in combination with injectable therapies.

## CONSIDERING ORAL THERAPY IN COMBINATION WITH INJECTABLE THERAPIES



### METFORMIN



Continue treatment with metformin

### SGLT2i



If on SGLT2i, continue treatment

Consider adding SGLT2i if

- Established CVD
- If HbA<sub>1c</sub> above target or as weight reduction aid

### TZD<sup>1</sup>



Stop TZD when commencing insulin OR reduce dose



Beware

- DKA (euglycemic)
- Instruct on sick-day rules
- Do not down-titrate insulin over-aggressively

### SULFONYLUREA



If on SU, stop or reduce dose by 50% when basal insulin initiated

### DPP-4i



Stop DPP-4i if GLP-1 RA initiated



Consider stopping SU if prandial insulin initiated or on a premix regimen

1. Contraindicated in some countries, consider lower dose. This combination has a high risk of fluid retention and weight gain



# Summary

- Type 2 diabetes is a progressive disease.
- Individualize your patients' glycemic target based on patient and disease characteristics.
- Provide patient-centered care and use shared decision-making to overcome barriers to injectable therapy.
- Consider GLP-1 RA as the first injectable before insulin.
- Initiate appropriate basal insulin based in the individual patient's hypoglycemia risk, weight concerns, and cost considerations.



100 Years of Insulin Therapy: A long Successful Path



# Summary

- Basal insulin have a physiological maximum benefit around 0.8 units per Kg/day and prescribers should look beyond basal to prandial intervention.
- Intensification of therapy beyond basal can be accomplished through addition of GLP-1 RA or SGLT2 inhibitors.
- Addition of prandial insulin can be simplified by stepwise approach with close follow up and titration.
- Professional or intermittent CGM can illuminate need for intensification or directional changes in therapy.



100 Years of Insulin Therapy: A long Successful Path



# “Insulin is not the enemy it is the misuse of insulin that is the enemy.”

*Richard Aguilar*



100 Years of Insulin Therapy: A long Successful Path

